Artículos de revistas
Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation
Fecha
2016-10Registro en:
Petruskevicius, I.; Ludvigsen, M.; Hjortebjerg, R.; Sorensen, B. S.; Kamper, P.; et al.; Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation; Macmillan; Bone Marrow Transplantation; 51; 10; 10-2016; 1387-1390
0268-3369
1476-5365
CONICET Digital
CONICET
Autor
Petruskevicius, I.
Ludvigsen, M.
Hjortebjerg, R.
Sorensen, B. S.
Kamper, P.
Vase, M.
Oestgaard, L. G.
Nielsen, B.
Honoré, B.
Bjerre, M.
Rabinovich, Gabriel Adrián
D'Amore, F. A.
Resumen
Non-myeloablative hemopoietic stem cell transplantation (NM-HSCT) is often the only curative treatment option for patients with hematologic malignancies.1 However, the treatment is frequently complicated by significant morbidity and mortality, acute GvHD (aGvHD) and chronic GvHD (cGvHD) being among the major causes.